Fig. 2: MAbs binding and neutralization of diverse SARS-CoV-2 variants.
a Key substitutions in RBD in 19 previous and current variants. b Neutralization activity of the indicated antibodies against the SARS-CoV-2 variants examined in human Huh7 cells using a pseudovirus system. “/”: These antibodies show low neutralization activity against BA.1 and BA.2, therefore no further research against other Omicron variants were performed. c KD values of the indicated antibodies to RBD of various variants examined by SPR. Data were collected from two biological replicates and represented as means ± SD. d Competitive binding of the antibodies in BLI-based competitive binding assay. Inhibitory rate was shown as a percentage. Antibody A displaying > 50% inhibitory rate against antibody B means antibody A strongly competes with antibody B to bind the RBD. e Neutralizing titer IC50 values of the indicated antibodies against the authentic SARS-CoV-2 variants in FRNT assays. “/”: These antibodies show low neutralization activity. ND not detected. Data were collected from two biological replicates and represented as means ± SD.
